Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Studie for å evaluere farmakokinetikken (PK), sikkerhet og tolerabilitet opp til 6 år med intravenøs (i.v.) Secukinumab hos pediatriske deltakere med juvenil psoriasisartritt (JPsA).

6. november 2026 oppdatert av: Novartis Pharmaceuticals

En åpen, multisenterstudie for å evaluere farmakokinetikk, sikkerhet og tolerabilitet opp til 6 år med intravenøs Secukinumab-infusjoner hos pediatriske deltakere med juvenil psoriasisartritt

The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Detaljert beskrivelse

This is a multicenter, open-label study with an optional treatment extension period to evaluate pharmacokinetics, safety and tolerability (up to 6 years) of i.v. secukinumab in pediatric patients with JPsA.

Studietype

Intervensjonell

Registrering (Antatt)

20

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

  • Navn: Novartis Pharmaceuticals

Studiesteder

    • California
      • Loma Linda, California, Forente stater, 92354
        • Rekruttering
        • Loma Linda University Health
        • Ta kontakt med:
        • Hovedetterforsker:
          • Wendy De La Pena
    • Florida
      • Gainesville, Florida, Forente stater, 32610-8068
        • Rekruttering
        • University of Florida
        • Hovedetterforsker:
          • Christian Oliveros
        • Ta kontakt med:
    • Illinois
      • Chicago, Illinois, Forente stater, 60611
        • Rekruttering
        • Ann and Robert H Lurie Childs Hosp
        • Hovedetterforsker:
          • Pooja Patel
        • Ta kontakt med:
    • New York
      • New York, New York, Forente stater, 10032
        • Rekruttering
        • Col Uni Med Center New York Presby
        • Ta kontakt med:
        • Hovedetterforsker:
          • Lisa Imundo
    • North Carolina
      • Charlotte, North Carolina, Forente stater, 28203
        • Rekruttering
        • Levine Childrens Hospital
        • Hovedetterforsker:
          • Sheetal Vora
        • Ta kontakt med:
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45229
        • Rekruttering
        • Cincinnati Childrens Hospital
        • Hovedetterforsker:
          • Hermine Brunner
        • Ta kontakt med:
      • Cleveland, Ohio, Forente stater, 44106-5028
        • Rekruttering
        • Univ Hosp Cleveland Medical Center
        • Hovedetterforsker:
          • Ezequiel Borgia
        • Ta kontakt med:
    • Oregon
      • Portland, Oregon, Forente stater, 97232
        • Rekruttering
        • Legacy Emanuel Research Hosp Portland
        • Hovedetterforsker:
          • Daniel Joseph Kingsbury
        • Ta kontakt med:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15224
        • Rekruttering
        • Childrens Hosp Pittsburgh UPMC
        • Hovedetterforsker:
          • Margalit Rosenkranz
        • Ta kontakt med:
    • Texas
      • El Paso, Texas, Forente stater, 79902
        • Rekruttering
        • Texas Arthritis Center
        • Hovedetterforsker:
          • Sanjay Chabra
        • Ta kontakt med:
    • Utah
      • Salt Lake City, Utah, Forente stater, 84113
        • Rekruttering
        • University of Utah
        • Ta kontakt med:
        • Hovedetterforsker:
          • Peter Chiraseveenuprapund

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

2 år til 17 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

  • Participants parent's or legal representative(s) written informed consent and child's assent, if appropriate, must be obtained before any study related activity or assessment is performed. Of note, if the participant reaches age of consent (as per local law) during the study, they will also need to sign the corresponding study ICF (Informed Consent Form).

  • Males and females ≥2 years old to <18 years old at the time of screening.

  • Confirmed diagnosis of JPsA according to the modified International League of Associations for Rheumatology (ILAR) classification criteria that must have occurred at least 6 months prior to screening.

  • Active JPsA disease defined as ≥3 active joints (swollen or if not swollen must be both tender and limited range of motion) at baseline (BSL).

  • Inadequate response (≥1 month) or intolerance to ≥1 Non-Steroidal Anti-Inflammatory Drug (NSAID) at screening.

  • Inadequate response (≥2 months) or intolerance to ≥ 1 Disease Modifying Anti-Rheumatic Drug (DMARD) at screening.

  • Concomitant use of the following second-line agents such as disease-modifying and/or immunosuppressive drugs to treat the JPsA will be allowed:

    • Stable dose of methotrexate (MTX) (maximum of 20 mg/ m2 BSA/ week) for at least 4 weeks prior to the BSL visit, with folic/folinic acid supplementation (according to standard medical practice of the center).
    • Stable dose of an oral corticosteroid (CS) at a prednisone equivalent dose of <0.2 mg/kg/day or up to 10 mg/day maximum, whichever is less, for at least 7 days prior to BSL.
    • Stable dose of no more than one NSAID for at least 1 week prior to BSL.

Key Exclusion Criteria:

  • Participants with body weight less than 10 kg at screening.
  • Use of other investigational drugs within 4 weeks or 5 half-lives of BSL, or until the expected pharmacodynamic effect has returned to BSL, whichever is longer.
  • History of hypersensitivity to study drug or its excipients or to drugs of similar chemical classes.
  • Participants with active inflammatory bowel disease or active uveitis at screening or BSL.
  • Fulfilling diagnostic criteria for any International League of Associations for Rheumatology (ILAR ) juvenile idiopathic arthritis (JIA) category other than JPsA at BSL.
  • Participants treated with prohibited medication
  • Participants taking any non-biologic DMARD at screening except for MTX.
  • Any medical or psychiatric condition which, in the investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.

Other inclusion/exclusion criteria may apply

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Secukinumab

Secukinumab administered intravenously in pediatric participants with JPsA

Intravenous secukinumab

Andre navn:
  • AIN457

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Maximum concentration on Day 1
Tidsramme: Pre-infusion and end of infusion (EOI) at Day 1

Maximum concentration of secukinumab on Day 1

Pre-infusion and end of infusion (EOI) at Day 1
Maximum concentration at steady-state (Cmax, ss)
Tidsramme: Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365

Maximum concentration at steady-state.

Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
Minimum concentration at steady-state (Cmin, ss)
Tidsramme: Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365

Minimum concentration at steady-state

Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
Area under the concentration-time curve at steady-state (AUCtau, ss)
Tidsramme: Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365

Area under the concentration-time curve at steady-state during a dosing interval

Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365
Average concentration at steady-state (Cavg,ss)
Tidsramme: Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365

Average concentration at steady-state

Preinfusion and EOI on Day 1, Day 29 and Day 57; weekly on Day 64, Day 71, Day 78, and Day 85; on Day 141 (pre-infusion if participant continues to the optional extension treatment or anytime during the visit if does not continue); preinfusion on Day 365

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: Up to Week 20

Number of participants with AEs and SAEs as a measure of safety and tolerability

Up to Week 20
Number of participants with clinically significant changes in clinical laboratory measures and vital signs.
Tidsramme: Up to Week 20

Number of participants with clinically significant changes in clinical laboratory measures and vital signs as a measure of safety and tolerability

Up to Week 20

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

24. september 2025

Primær fullføring (Antatt)

31. oktober 2029

Studiet fullført (Antatt)

11. mars 2031

Datoer for studieregistrering

Først innsendt

20. desember 2024

Først innsendt som oppfylte QC-kriteriene

20. desember 2024

Først lagt ut (Faktiske)

27. desember 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere